In recent years, 'long-acting' bronchodilators have been introduced. Long-acting bronchodilators have an extended period of action that reduces the need for multiple dosing, and are also more ...

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...

Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Clenbuterol has not been approved by the U.S. Food and Drug Administration (FDA) as an ingredient for any drugs for humans, ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to ...

This study highlights the benefits of anti-inflammatory inhalers in asthma management, showing reduced complications and ...

Compared with bronchodilator-only relievers ... All included trials of fast-onset, long-acting beta-agonists (alone or combined with an ICS) as a reliever therapy evaluated formoterol.